search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


The Dutch ITP-registry, a national web-based tool for collection of diagnostic, therapeutical and evaluation data from patients with chronic immune trombocytopenic purpura.


- candidate number8032
- NTR NumberNTR2308
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR28-apr-2010
- Secondary IDs 
- Public TitleThe Dutch ITP-registry, a national web-based tool for collection of diagnostic, therapeutical and evaluation data from patients with chronic immune trombocytopenic purpura.
- Scientific TitleStart treatment in chronic ITP (STiC) registry.
- ACRONYMSTiC registry
- hypothesisThe mission of the chronic ITP registry is to improve the knowledge of the treatment and course of patients with persistent of chronic ITP. The objective of the registry is to get more insight in the number of patients that need a treatment for chronic ITP, what the effectivity, safety and cost-effectiveness is of the different treatment modalities in a non-selected patient population with chronic ITP. By collecting and analysing data, questions can be answered such as:
1. How many patients need a treatment for chronic ITP?
2. Does the treatment work in non-selected patient group with chronic ITP?
3. What is the frequency and severity of side effects induced by new drugs in a non-selected patients group with chronic ITP?
4. What is the cost-effectiveness?
5. What is the quality of life in respect to treatment?
Obviously, given the nature of the registry, only descriptive and non direct comparable results can be obtained.
- Healt Condition(s) or Problem(s) studiedEfficacy, Safety, Quality of life, Cost-effectiveness , Treatment
- Inclusion criteriaAdult patients (M/F) with chronic or persistent ITP (with history of splenectomy) needing additional treatment (inc. wait-and-see patients qualifying for ITP but not activily being treated but in follow-up).
- Exclusion criteria1. Minors;
2. Patients with acute or secundairy ITP.
- mec approval receivedyes
- multicenter trialyes
- randomisedno
- groupParallel
- TypeSingle arm
- Studytypeobservational
- planned startdate 1-okt-2010
- planned closingdate
- Target number of participants300
- InterventionsN/A
- Primary outcome1. How many patients need a treatment for chronic ITP;
2. Does the treatment work in non-selected patient group with chronic ITP;
3. What is the frequency and severity of side effects induced by new drugs in a non-selected patients group with chronic ITP;
4. What is the cost-effectiveness.
- Secondary outcomeQuality of life.
- TimepointsRelevant patient data and QoL is entered in the national database twice a year after visitation treating physician.
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIESDr. R. Fijheer
- CONTACT for SCIENTIFIC QUERIESDr. J.J. Zwaginga
- Sponsor/Initiator
- Funding
(Source(s) of Monetary or Material Support)
Amgen, GlaxoSmithKline, Roche Nederland BV
- PublicationsN/A
- Brief summaryImmune thrombocytopenic purpura (ITP) is an immune-mediated acquired disease, characterized by a decreased platelet count and, depending upon the degree of thrombocytopenia, an increased risk of bleeding. A national guideline for the treatment of acute, persistent, and chronic ITP has been written by the Dutch working party on non-malignant hematology. However, treatment-related decisions still remain principally dependent on clinical expertise rather than clinical trial evidence. Introduction of new classes of therapeutic agents have enlarged the therapeutical arsenal even though the position of these agents is not completely clear.
With the ITP registry the knowledge of treatment and course of patients with chronic or persistent ITP is greatly improved. More Insight is obtained in the number of patients that need treatment, frequency and severity of side effects and cost-effectiveness.
Relevant data on every chronic ITP patient needing additional treatment (including wait-and-see patients, qualifying for ITP but not actively being treated but in follow-up) will be entered in the national web-based database. The working party on non-malignant haematology will ask all haematologists in the Netherlands to include their patients. Requests for use and study of aggregate data from the database are handled by the steering committee. The steering committee produces a yearly report of the status and use of the database, together with a summary of data.
- Main changes (audit trail)
- RECORD28-apr-2010 - 9-mei-2010


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl